Cargando…
In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model
PURPOSE: Histone deacetylase inhibitors are promising new substances in cancer therapy and have also been shown to sensitize different tumor cells to irradiation (XRT). We explored the effect as well as the radiosensitizing properties of suberoylanilide hydroxamic acid (SAHA) in vivo in a malignant...
Autores principales: | Thiemann, Markus, Oertel, Susanne, Ehemann, Volker, Weichert, Wilko, Stenzinger, Albrecht, Bischof, Marc, Weber, Klaus-J, Perez, Ramon Lopez, Haberkorn, Uwe, Kulozik, Andreas E, Debus, Jürgen, Huber, Peter E, Battmann, Claudia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342162/ https://www.ncbi.nlm.nih.gov/pubmed/22458853 http://dx.doi.org/10.1186/1748-717X-7-52 |
Ejemplares similares
-
Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy
por: Blattmann, Claudia, et al.
Publicado: (2015) -
Combination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sarcoma cell lines
por: Oertel, Susanne, et al.
Publicado: (2011) -
The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Alleviates Salinity Stress in Cassava
por: Patanun, Onsaya, et al.
Publicado: (2017) -
Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma
por: O'Connor, O A
Publicado: (2006) -
In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC)
por: Tambunan, Usman SF, et al.
Publicado: (2011)